Form 4 for LCTX Lineage Cell Therapeutics, Inc.
Accepted 2025-02-12 00:00:00 ET · period of report 2025-02-11 · accession 0000950170-25-018887 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-12 | 2025-02-11 | LCTX | Culley Brian M | Pres, CEO, Dir | M - OptEx | — | +31.2K | 226.1K | +16% | — |
| D | 2025-02-12 | 2025-02-11 | LCTX | Culley Brian M | Pres, CEO, Dir | F - Tax | $0.65 | -12.5K | 213.5K | -6% | -$8,156 |
| D | 2025-02-12 | 2025-02-11 | LCTX | Culley Brian M | Pres, CEO, Dir | M - OptEx | $0.00 | -31.2K | 31.2K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2025-02-11 | M | A | 31,249 | — | 226,091 | D | — | — | (F1) Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis. (F2) Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options. |
| 2 | Common | Common Shares | 2025-02-11 | F | D | 12,547 | $0.65 | 213,544 | D | — | — | (F3) Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 31,249 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction (F2) Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options. |
| 3 | Derivative | Restricted Stock Units | 2025-02-11 | M | D | 31,249 | $0.00 | 31,250 | D | $0.00 · — to — | 31,249 Common Shares | (F4) The Reporting Person was granted 124,997 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026. |